{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:18:35Z","timestamp":1785395915377,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,27]]},"DOI":"10.7759\/cureus.25380","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T08:32:39Z","timestamp":1653640359000},"source":"Crossref","is-referenced-by-count":14,"title":["The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Andrew","family":"Ndakotsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govinathan","family":"Vivekanandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1055\/a-0784-8827","article-title":"Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments","volume":"57","author":"Roeb E","year":"2019","unstructured":"Roeb E, Geier A. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. Z Gastroenterol. 2019, 57:508-17. 10.1055\/a-0784-8827","journal-title":"Z Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang DQ","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021, 18:223-38. 10.1038\/s41575-020-00381-6","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S265286","article-title":"Experimental and investigational targeted therapies for the management of fibrosis in NASH: an update","volume":"13","author":"Huisman TM","year":"2021","unstructured":"Huisman TM, Dieterich DT, Friedman SL. Experimental and investigational targeted therapies for the management of fibrosis in NASH: an update. J Exp Pharmacol. 2021, 13:329-38. 10.2147\/JEP.S265286","journal-title":"J Exp Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i47.8263","article-title":"Clinical epidemiology and disease burden of nonalcoholic fatty liver disease","volume":"23","author":"Perumpail BJ","year":"2017","unstructured":"Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017, 23:8263-76. 10.3748\/wjg.v23.i47.8263","journal-title":"World J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1966","article-title":"High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels","volume":"100","author":"Portillo-Sanchez P","year":"2015","unstructured":"Portillo-Sanchez P, Bril F, Maximos M, et al.. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 2015, 100:2231-8. 10.1210\/jc.2015-1966","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02482.x","article-title":"Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors","volume":"31","author":"Leite NC","year":"2011","unstructured":"Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, Salles GF. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 2011, 31:700-6. 10.1111\/j.1478-3231.2011.02482.x","journal-title":"Liver Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s1542-3565(04)00014-x","article-title":"Nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"2","author":"Younossi ZM","year":"2004","unstructured":"Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004, 2:262-5. 10.1016\/s1542-3565(04)00014-x","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon G","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011, 34:274-85. 10.1111\/j.1365-2036.2011.04724.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options","volume":"1","author":"Gastaldelli A","year":"2019","unstructured":"Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep. 2019, 1:312-28. 10.1016\/j.jhepr.2019.07.002","journal-title":"JHEP Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-1684-1","article-title":"Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009","volume":"53","author":"DeFronzo RA","year":"2010","unstructured":"DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010, 53:1270-87. 10.1007\/s00125-010-1684-1","journal-title":"Diabetologia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4183\/aeb.2020.223","article-title":"The effects of Realsil (silybin-phospholipid-vitamin e complex) on liver enzymes in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steato-hepatitis (NASH): a systematic review and meta-analysis of RCTs","volume":"16","author":"Derakhshandeh-Rishehri SM","year":"2020","unstructured":"Derakhshandeh-Rishehri SM, Heidari-Beni M, Eftekhari MH. The effects of Realsil (silybin-phospholipid-vitamin e complex) on liver enzymes in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steato-hepatitis (NASH): a systematic review and meta-analysis of RCTs. Acta Endocrinol (Buchar). 2020, 16:223-31. 10.4183\/aeb.2020.223","journal-title":"Acta Endocrinol (Buchar)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.01.013","article-title":"Noninvasive diagnosis of nonalcoholic fatty liver disease: are we there yet?","volume":"65","author":"Alkhouri N","year":"2016","unstructured":"Alkhouri N, Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease: are we there yet?. Metabolism. 2016, 65:1087-95. 10.1016\/j.metabol.2016.01.013","journal-title":"Metabolism"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004947","article-title":"Thiazolidinediones for nonalcoholic steatohepatitis: a meta-analysis of randomized clinical trials","volume":"95","author":"He L","year":"2016","unstructured":"He L, Liu X, Wang L, Yang Z. Thiazolidinediones for nonalcoholic steatohepatitis: a meta-analysis of randomized clinical trials. Medicine (Baltimore). 2016, 95:e4947. 10.1097\/MD.0000000000004947","journal-title":"Medicine (Baltimore)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.05.013","article-title":"Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review","volume":"65","author":"Polyzos SA","year":"2016","unstructured":"Polyzos SA, Mantzoros CS. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review. Metabolism. 2016, 65:1297-306. 10.1016\/j.metabol.2016.05.013","journal-title":"Metabolism"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i6.802","article-title":"What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?","volume":"19","author":"Finelli C","year":"2013","unstructured":"Finelli C, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?. World J Gastroenterol. 2013, 19:802-12. 10.3748\/wjg.v19.i6.802","journal-title":"World J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i21.5096","article-title":"Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease","volume":"22","author":"Jamali R","year":"2016","unstructured":"Jamali R, Razavizade M, Arj A, Aarabi MH. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease. World J Gastroenterol. 2016, 22:5096-103. 10.3748\/wjg.v22.i21.5096","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.10.2968","article-title":"The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects","volume":"51","author":"Yu JG","year":"2002","unstructured":"Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002, 51:2968-74. 10.2337\/diabetes.51.10.2968","journal-title":"Diabetes"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00842","article-title":"Examining the potential of developing and implementing use of adiponectin-targeted therapeutics for metabolic and cardiovascular diseases","volume":"10","author":"Liu Y","year":"2019","unstructured":"Liu Y, Vu V, Sweeney G. Examining the potential of developing and implementing use of adiponectin-targeted therapeutics for metabolic and cardiovascular diseases. Front Endocrinol (Lausanne). 2019, 10:842. 10.3389\/fendo.2019.00842","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6:e1000097. 10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/s1542-3565(04)00457-4","article-title":"A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis","volume":"2","author":"Sanyal AJ","year":"2004","unstructured":"Sanyal AJ, Mofrad PS, Contos MJ, et al.. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004, 2:1107-1115. 10.1016\/s1542-3565(04)00457-4","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort R","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K, et al.. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006, 355:2297-307. 10.1056\/NEJMoa060326","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal GP","year":"2008","unstructured":"Aithal GP, Thomas JA, Kaye PV, et al.. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008, 135:1176-84. 10.1053\/j.gastro.2008.06.047","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23270","article-title":"Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial","volume":"51","author":"Ratziu V","year":"2010","unstructured":"Ratziu V, Charlotte F, Bernhardt C, et al.. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology. 2010, 51:445-53. 10.1002\/hep.23270","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal AJ","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, et al.. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010, 362:1675-85. 10.1056\/NEJMoa0907929","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20012","article-title":"A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis","volume":"39","author":"Promrat K","year":"2004","unstructured":"Promrat K, Lutchman G, Uwaifo GI, et al.. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004, 39:188-96. 10.1002\/hep.20012","journal-title":"Hepatology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2012.10.010","article-title":"A randomized controlled trial comparing efficacy of pentoxifylline and pioglitazone on metabolic factors and liver histology in patients with non-alcoholic steatohepatitis","volume":"2","author":"Sharma BC","year":"2012","unstructured":"Sharma BC, Kumar A, Garg V, Reddy RS, Sakhuja P, Sarin SK. A randomized controlled trial comparing efficacy of pentoxifylline and pioglitazone on metabolic factors and liver histology in patients with non-alcoholic steatohepatitis. J Clin Exp Hepatol. 2012, 2:333-7. 10.1016\/j.jceh.2012.10.010","journal-title":"J Clin Exp Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2016\/19887.8336","article-title":"Comparative effect of insulin sensitizers and statin on metabolic profile and ultrasonographical score in non alcoholic fatty liver disease","volume":"10","author":"Rana H","year":"2016","unstructured":"Rana H, Yadav SS, Reddy HD, Singhal S, Singh DK, Usman K. Comparative effect of insulin sensitizers and statin on metabolic profile and ultrasonographical score in non alcoholic fatty liver disease. J Clin Diagn Res. 2016, 10:OC19-23. 10.7860\/JCDR\/2016\/19887.8336","journal-title":"J Clin Diagn Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001369","article-title":"Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial","volume":"31","author":"Anushiravani A","year":"2019","unstructured":"Anushiravani A, Haddadi N, Pourfarmanbar M, Mohammadkarimi V. Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. Eur J Gastroenterol Hepatol. 2019, 31:613-7. 10.1097\/MEG.0000000000001369","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi K","year":"2016","unstructured":"Cusi K, Orsak B, Bril F, et al.. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016, 165:305-15. 10.7326\/M15-1774","journal-title":"Ann Intern Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/nature05482","article-title":"Mechanisms linking obesity to insulin resistance and type 2 diabetes","volume":"444","author":"Kahn SE","year":"2006","unstructured":"Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006, 444:840-6. 10.1038\/nature05482","journal-title":"Nature"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50420","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone","volume":"38","author":"Neuschwander-Tetri BA","year":"2003","unstructured":"Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003, 38:1008-17. 10.1053\/jhep.2003.50420","journal-title":"Hepatology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03553.x","article-title":"A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis","volume":"96","author":"Caldwell SH","year":"2001","unstructured":"Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001, 96:519-25. 10.1111\/j.1572-0241.2001.03553.x","journal-title":"Am J Gastroenterol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt EM","year":"1999","unstructured":"Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999, 94:2467-74. 10.1111\/j.1572-0241.1999.01377.x","journal-title":"Am J Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner DE","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, et al.. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005, 41:1313-21. 10.1002\/hep.20701","journal-title":"Hepatology"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50193","article-title":"Nonalcoholic steatohepatitis: summary of an AASLD single topic conference","volume":"37","author":"Neuschwander-Tetri BA","year":"2003","unstructured":"Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003, 37:1202-19. 10.1053\/jhep.2003.50193","journal-title":"Hepatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/87846-the-role-of-thiazolidinediones-in-the-amelioration-of-nonalcoholic-fatty-liver-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:35:49Z","timestamp":1707507349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/87846-the-role-of-thiazolidinediones-in-the-amelioration-of-nonalcoholic-fatty-liver-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.25380","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,27]]}}}